Reni Benjamin
Stock Analyst at JMP Securities
(1.43)
# 3,502
Out of 5,030 analysts
173
Total ratings
40.56%
Success rate
-14.25%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Reiterates: Market Perform | n/a | $1.23 | - | 8 | Aug 4, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $37.36 | - | 10 | May 15, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $26 → $22 | $8.17 | +169.28% | 14 | May 2, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.80 | +151.19% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.83 | +20.53% | 9 | Mar 31, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $87.57 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $0.99 | - | 5 | Mar 7, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $1.60 | +150.00% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.88 | +113.33% | 1 | Aug 8, 2022 | |
| ADVM Adverum Biotechnologies | Upgrades: Market Perform | n/a | $4.29 | - | 4 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.37 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $6.56 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $16 | $0.20 | +7,896.00% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $14.36 | -30.36% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $5.03 | -0.60% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $9.84 | +184.55% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $19.09 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $20.99 | +90.57% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $1.48 | - | 7 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.18 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $1.19 | +236.13% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.01 | - | 10 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $8.98 | -10.91% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $46.25 | +29.73% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $8.29 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $234.25 | +34.47% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $92.30 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $240.21 | +10.32% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $4.95 | +243.43% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.55 | - | 3 | Nov 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $11.73 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.65 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $34.67 | -65.39% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $16.94 | - | 1 | Nov 15, 2017 |
Allogene Therapeutics
Aug 4, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.23
Upside: -
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $37.36
Upside: -
Bicycle Therapeutics
May 2, 2025
Maintains: Market Outperform
Price Target: $26 → $22
Current: $8.17
Upside: +169.28%
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.80
Upside: +151.19%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.83
Upside: +20.53%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $87.57
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.99
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $1.60
Upside: +150.00%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.88
Upside: +113.33%
Adverum Biotechnologies
Nov 12, 2020
Upgrades: Market Perform
Price Target: n/a
Current: $4.29
Upside: -
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.37
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $6.56
Upside: -
Oct 22, 2018
Maintains: Outperform
Price Target: $20 → $16
Current: $0.20
Upside: +7,896.00%
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $14.36
Upside: -30.36%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $5.03
Upside: -0.60%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $9.84
Upside: +184.55%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $19.09
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $20.99
Upside: +90.57%
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.48
Upside: -
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.18
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $1.19
Upside: +236.13%
Mar 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.01
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $8.98
Upside: -10.91%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $46.25
Upside: +29.73%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.29
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $234.25
Upside: +34.47%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $92.30
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $240.21
Upside: +10.32%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $4.95
Upside: +243.43%
Nov 15, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $0.55
Upside: -
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $11.73
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.65
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $34.67
Upside: -65.39%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $16.94
Upside: -